Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925964 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL30600458 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL9331674 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL29400837 | 0.96 | KEAP1 (0.57) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL30600462 | 0.96 | KEAP1 (0.57) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL4951645 | 0.94 | DPP8 (0.54) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL17073673 | 0.91 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL6281421 | 0.89 | DPP8 (0.59) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL25003569 | 0.88 | KEAP1 (0.56) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL18541545 | 0.87 | DPP8 (0.53) | KEAP1NFE2L2DPP8DPP7SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | WASHINGTON UNIVERSITY (US) | 2022-12-01 | — | — | US | claimed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | claimed |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250327074-A1 | THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS | SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-4704380-A | TETRADECAPEPTIDES | WASHINGTON UNIVERSITY (US) | 1987-11-03 | — | — | US | disclosed |
| US-4697002-A | BLOOD METAL CONCENTRATIONS | KEMPE TOMAS G | 1987-09-29 | — | — | US | disclosed |
| EP-0233838-A2 | Neurite-promoting factor and process for the manufacture thereof | INCYTE PHARMACEUTICALS, INC. (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4687839-A | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents | KEMPE TOMAS G | 1987-08-18 | — | — | US | disclosed |
| EP-0220157-A2 | Mitogenic peptides | WASHINGTON UNIVERSITY (US) | 1987-04-29 | — | — | EP | disclosed |
| US-4652627-A | BLOOD METAL CONCENTRATIONS | KEMPE TOMAS G (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0212912-A2 | Calcitonin analogs with C-therminal D-amino acid substituents | Kempe, Tomas G. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4644054-A | LOWERING BLOOD CALCIUM | KEMPE TOMAS G | 1987-02-17 | — | — | US | disclosed |
| US-4127522-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | KEAP1 1023/4885NFE2L2 1471/4885DPP8 200/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | KEAP1 2182/4885NFE2L2 1332/4885DPP8 88/4885 |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | KEAP1 2075/4885NFE2L2 3476/4885DPP8 791/4885 |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | TMPRSS2, PRSS1, PRSS2 | KEAP1 699/4885NFE2L2 2080/4885DPP8 147/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | KEAP1 3295/4885NFE2L2 3928/4885DPP8 1056/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | KEAP1 1497/4885NFE2L2 1070/4885DPP8 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.